Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study. (4th May 2017)

• Record Type: Journal Article
• Authors: Posso, Margarita; Corominas, Josep M.; Serrano, Laia; Román, Marta; Torá‐Rocamora, Isabel; Domingo, Laia; Romero, Anabel; Quintana, María Jesús; Vernet‐Tomas, María; Baré, Marisa; Vidal, Carmen; Sánchez, Mar; Saladié, Francina; Natal, Carmen; Ferrer, Joana; Servitja, Sònia; Sala, María; Castells, Xavier
• Other Names: Burón Andrea investigator.; Rodríguez‐Arana Ana investigator.; Romero Ana investigator.; Vernet Mar investigator.; Andreu Xavier investigator.; Milà Núria investigator.; López‐Vilaró Laura investigator.; Fernández‐Somoano Ana investigator.; Galceran Jaume investigator.; Espinàs Josep Alfons investigator.
• Is Part Of: Cancer medicine. Volume 6:Number 6(2017:Jun.)
• Page Start: 1482
• Page End: 1489
• Publication Date: 2017-05-04
• Subjects: Benign breast disease -- biomarkers -- breast cancer -- early detection -- screening; 616.994005
• DOI: 10.1002/cam4.1080
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Women with benign breast diseases (BBD) have a high risk of breast cancer. However, no biomarkers have been clearly established to predict cancer in these women. Our aim was to explore whether estrogen receptor (ER), progesterone receptor (PR), and Ki67 expression stratify risk of breast cancer in screened women with BBD. We conducted a nested case–control study. Women with breast cancer and prior BBDs (86 cases) were matched to women with prior BBDs who were free from breast cancer (172 controls). The matching factors were age at BBD diagnosis, type of BBD, and follow‐up time since BBD diagnosis. ER, PR, and Ki67 expression were obtained from BBDs' specimens. Conditional logistic regression was used to estimate odds ratios (ORs), and 95% confidence intervals (CIs) of breast cancer risk according to ER, PR, and Ki67 expression. Women with >90% of ER expression had a higher risk of breast cancer (OR = 2.63; 95% CI: 1.26–5.51) than women with ≤70% of ER expression. Similarly, women with >80% of PR expression had a higher risk of breast cancer (OR = 2.22; 95% CI: 1.15–4.27) than women with ≤40% of PR expression. Women with proliferative disease and ≥1% of Ki67 expression had a nonsignificantly increased risk of breast cancer (OR = 1.16; 95% CI: 0.46–2.90) than women with <1% of Ki67 expression. A high expression of ER and PR in BBD is associated with an increased risk of subsequent breast cancer. In proliferative disease, high Ki67 expression may also have an increased risk. This information is helpful to better characterize BBD and is one more step toward personalizing the clinical management of these women. Abstract : Today, no biomarkers have been clearly established to predict cancer in women diagnosed with benign breast disease (BBD). We found that a high expression of estrogen receptor and progesterone receptor expression in BBD is associated with an increased risk of subsequent breast cancer and that Ki67 expression may stratify risk in women with proliferative diseases.